Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Treatment is recommended for a maximum of two years
tirzepatide also led to a mean body weight reduction of 18.1% from baseline, compared to 1.3% from baseline for placebo
You can determine your eligibility by taking our free assessment quiz, which evaluates your health history and weight loss goals
Ongoing risk-benefit assessment is essential
Tirzepatide for diabetes and obesity: A new window to the treatment of non-alcoholic steatohepatitis
GLP-1 receptor agonists like semaglutide work in the opposite directionthey suppress appetite, slow gastric emptying, and improve insulin secretion to lower blood sugar
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 21.52
US$ 29.31
US$ 26.72
